These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 29089230)

  • 21. Tetra-substituted imidazoles as a new class of inhibitors of the p53-MDM2 interaction.
    Vaupel A; Bold G; De Pover A; Stachyra-Valat T; Lisztwan JH; Kallen J; Masuya K; Furet P
    Bioorg Med Chem Lett; 2014 May; 24(9):2110-4. PubMed ID: 24704029
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation.
    Qin JJ; Wang W; Voruganti S; Wang H; Zhang WD; Zhang R
    Oncotarget; 2015 Feb; 6(5):2623-40. PubMed ID: 25739118
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis and in vitro and in vivo antitumour activity of 3-benzylideneindolin-2-one derivatives, a novel class of small-molecule inhibitors of the MDM2-p53 interaction.
    Zheng GH; Shen JJ; Zhan YC; Yi H; Xue ST; Wang Z; Ji XY; Li ZR
    Eur J Med Chem; 2014 Jun; 81():277-88. PubMed ID: 24852275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structure-activity relationship and antitumor activity of thio-benzodiazepines as p53-MDM2 protein-protein interaction inhibitors.
    Guo Z; Zhuang C; Zhu L; Zhang Y; Yao J; Dong G; Wang S; Liu Y; Chen H; Sheng C; Miao Z; Zhang W
    Eur J Med Chem; 2012 Oct; 56():10-6. PubMed ID: 22940704
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergistic roles of p53 and HIF1α in human renal cell carcinoma-cell apoptosis responding to the inhibition of mTOR and MDM2 signaling pathways.
    Liu QJ; Shen HL; Lin J; Xu XH; Ji ZG; Han X; Shang DH; Yang PQ
    Drug Des Devel Ther; 2016; 10():745-55. PubMed ID: 26937175
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Upregulation of p53 through induction of MDM2 degradation: Anthraquinone analogs.
    Draganov AB; Yang X; Anifowose A; De La Cruz LKC; Dai C; Ni N; Chen W; De Los Santos Z; Gu L; Zhou M; Wang B
    Bioorg Med Chem; 2019 Sep; 27(17):3860-3865. PubMed ID: 31324563
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proposing novel MDM2 inhibitors: Combined physics-driven high-throughput virtual screening and in vitro studies.
    Aydin G; Paksoy MN; Orhan MD; Avsar T; Yurtsever M; Durdagi S
    Chem Biol Drug Des; 2020 Jul; 96(1):684-700. PubMed ID: 32691963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A fluorinated indole-based MDM2 antagonist selectively inhibits the growth of p53
    Skalniak L; Twarda-Clapa A; Neochoritis CG; Surmiak E; Machula M; Wisniewska A; Labuzek B; Ali AM; Krzanik S; Dubin G; Groves M; Dömling A; Holak TA
    FEBS J; 2019 Apr; 286(7):1360-1374. PubMed ID: 30715803
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency.
    Hardcastle IR; Liu J; Valeur E; Watson A; Ahmed SU; Blackburn TJ; Bennaceur K; Clegg W; Drummond C; Endicott JA; Golding BT; Griffin RJ; Gruber J; Haggerty K; Harrington RW; Hutton C; Kemp S; Lu X; McDonnell JM; Newell DR; Noble ME; Payne SL; Revill CH; Riedinger C; Xu Q; Lunec J
    J Med Chem; 2011 Mar; 54(5):1233-43. PubMed ID: 21314128
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and Optimization of New 3,6-Disubstitutedindole Derivatives and Their Evaluation as Anticancer Agents Targeting the MDM2/MDMx Complex.
    Rezk MS; Abdel-Halim M; Keeton A; Franklin D; Bauer M; Boeckler FM; Engel M; Hartmann RW; Zhang Y; Piazza GA; Abadi AH
    Chem Pharm Bull (Tokyo); 2016; 64(1):34-41. PubMed ID: 26726742
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.
    Tovar C; Graves B; Packman K; Filipovic Z; Higgins B; Xia M; Tardell C; Garrido R; Lee E; Kolinsky K; To KH; Linn M; Podlaski F; Wovkulich P; Vu B; Vassilev LT
    Cancer Res; 2013 Apr; 73(8):2587-97. PubMed ID: 23400593
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of AM-7209, a potent and selective 4-amidobenzoic acid inhibitor of the MDM2-p53 interaction.
    Rew Y; Sun D; Yan X; Beck HP; Canon J; Chen A; Duquette J; Eksterowicz J; Fox BM; Fu J; Gonzalez AZ; Houze J; Huang X; Jiang M; Jin L; Li Y; Li Z; Ling Y; Lo MC; Long AM; McGee LR; McIntosh J; Oliner JD; Osgood T; Saiki AY; Shaffer P; Wang YC; Wortman S; Yakowec P; Ye Q; Yu D; Zhao X; Zhou J; Medina JC; Olson SH
    J Med Chem; 2014 Dec; 57(24):10499-511. PubMed ID: 25384157
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Diarylpentanoid with Potential Activation of the p53 Pathway: Combination of in silico Screening Studies, Synthesis, and Biological Activity Evaluation.
    Moreira J; Almeida J; Loureiro JB; Ramos H; Palmeira A; Pinto MM; Saraiva L; Cidade H
    ChemMedChem; 2021 Oct; 16(19):2969-2981. PubMed ID: 34170069
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dual targeting of MDM2 with a novel small-molecule inhibitor overcomes TRAIL resistance in cancer.
    Singh AK; Chauhan SS; Singh SK; Verma VV; Singh A; Arya RK; Maheshwari S; Akhtar MS; Sarkar J; Rangnekar VM; Chauhan PMS; Datta D
    Carcinogenesis; 2016 Nov; 37(11):1027-1040. PubMed ID: 27543608
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Discovery of Potential MDM2 Inhibitors: A Combination of Pharmacophore Modeling, Virtual Screening, Molecular Docking Studies, and in vitro/in vivo Biological Evaluation.
    Zhang X; Zhou C; Yang Y; Liu H; Wang S; Ding X; Wang H
    ChemMedChem; 2022 Feb; 17(4):e202100517. PubMed ID: 34806333
    [TBL] [Abstract][Full Text] [Related]  

  • 36. p53-Mdm2 inhibitors: patent review (2009 - 2010).
    Kamal A; Mohammed AA; Shaik TB
    Expert Opin Ther Pat; 2012 Feb; 22(2):95-105. PubMed ID: 22316395
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An Effective Virtual Screening Protocol To Identify Promising p53-MDM2 Inhibitors.
    Tortorella P; Laghezza A; Durante M; Gomez-Monterrey I; Bertamino A; Campiglia P; Loiodice F; Daniele S; Martini C; Agamennone M
    J Chem Inf Model; 2016 Jun; 56(6):1216-27. PubMed ID: 27269808
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma.
    Lu J; Guan S; Zhao Y; Yu Y; Wang Y; Shi Y; Mao X; Yang KL; Sun W; Xu X; Yi JS; Yang T; Yang J; Nuchtern JG
    Oncotarget; 2016 Dec; 7(50):82757-82769. PubMed ID: 27764791
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Screening of medicinal plant phytochemicals as natural antagonists of p53-MDM2 interaction to reactivate p53 functioning.
    Riaz M; Ashfaq UA; Qasim M; Yasmeen E; Ul Qamar MT; Anwar F
    Anticancer Drugs; 2017 Oct; 28(9):1032-1038. PubMed ID: 28723868
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction.
    Yu S; Qin D; Shangary S; Chen J; Wang G; Ding K; McEachern D; Qiu S; Nikolovska-Coleska Z; Miller R; Kang S; Yang D; Wang S
    J Med Chem; 2009 Dec; 52(24):7970-3. PubMed ID: 19928922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.